Should you use a research peptide like BPC-157 to heal an injury faster?

Ben GreenfieldMS · exercise physiologist, NSCA and ISSN certified by his own account, no clinical credential

Yes, and here is how he used it: doses, routes, sourcing and a supplier.

What it rests onHe reports treating bilateral golfer's elbow with '250mcg in my left elbow on one day, then 250mcg in my right elbow the next day, for a total of two weeks', treating a torn hamstring with ten days of daily intramuscular injections, and using an oral route for seven days. He gives a general range of 200 to 800 mcg, describes subcutaneous, intramuscular and oral administration, names a clinical supplier with a personal discount code, and states that the compound 'is surprisingly free of side effects' while acknowledging that 'long term studies in humans are relatively sparse'. He is explicit that it is not an approved drug and 'technically isn't allowed to be sold or advertised... for human consumption or human injection'. He holds no prescribing credential. Ten years later, on 30 Jul 2026, he answers the cancer worry rather than the evidence worry: the peptide's blood-vessel growth responds to injury and switches off in healthy tissue, unlike a tumour's, so a healthy person need not worry. He grants in the same segment that all the robust randomised evidence is in rodents, that there are no human trials, and that the friendliest published work comes from the group that originated the compound. His one hard line: if a cancer is present, he would not take it.

Judy ChoBCHN, FNTP · board-certified holistic nutritionist and functional nutritional therapy practitioner; no clinical licence recorded

Not yet, and not on your own. Peptides come after the foundations, inside a care plan, with the source checked first.

What it rests onHer article's own key takeaways, verbatim: 'Peptides may support root-cause healing when they are used at the right time and as part of a broader individualized care plan' and 'Peptides should not be used to bypass foundational healing work such as nutrition, sleep, environment, nervous system regulation, detox support, and inflammation reduction.' Read the whole bullet: she is NOT against peptides, and her position is about sequence, supervision and sourcing rather than about whether they work. Her closing section argues that peptides are one tool among many and that a knowledgeable practitioner should decide whether they fit. She runs a functional-medicine practice positioned to sell them, which makes this a claim against commercial interest.

Marion NestlePhD, MPH · Paulette Goddard Professor of Nutrition, Food Studies, and Public Health, Emerita, New York University

No. Anecdote is not evidence, and the approval everyone is citing was a political vote, not a scientific one.

What it rests onWriting the day after the advisory panel recommended six of seven peptides over the objections of FDA scientists, her verbatim assessment of the evidence is 'There is plenty of anecdotal evidence for the benefits of injected peptides, but no real science', and of the vote, that the panel was loaded with the health secretary's own appointees and 'six of his eight appointees sell peptides'. She notes the panel is advisory only.

Jessica B. SteierDrPH · public health scientist and health services researcher

No, and understand what the vote actually did: it changes who may sell these, not whether they work.

What it rests onThe most detailed account of the same hearing. She lists the hazards FDA scientists put on the record: immune responses to synthetic copies of molecules the body already makes, up to anaphylaxis, with taspoglutide as the precedent; doses that vary shot to shot because some of these peptides come out of solution; a carcinogenicity warning on epitalon; and products sold as BPC-157 containing different active molecules. She reports that at least seven panel members are involved in companies selling peptides, and that the randomised data on BPC-157 suggest it may perform no better than placebo. Her summary: 'Easier access is not the same thing as better evidence.' The hearing detail is credited to her colleague Dr Leigh Baxt.

Paul KnoepflerPhD · Professor of Cell Biology and Human Anatomy, UC Davis School of Medicine · stem cell and cancer biologist

Do not read the committee vote as a safety finding. Ask what approval status your specific peptide actually has.

What it rests onHe covered the same committee before and after it met. Before: the FDA's own meeting materials indicated the weight of evidence ran against allowing compounding, published reporting identified at least seven members with a track record of selling these peptides, and when he asked the FDA directly the agency told him there were no conflict-of-interest waivers in place. After: the first vote went 8-6 in favour of recommending BPC-157 compounding, the committee went on to recommend all but one of the peptides reviewed, and he reads the harm-reduction case the yes-voters made as one that ignores the inherent risks of the compounds. He is careful that the committee is advisory and the agency has not decided. He is a stem cell biologist reporting on a regulatory process, not a clinician advising a patient, and he sells nothing in this space.

Gabrielle LyonDO · osteopathic physician, muscle-centric medicine

Not on BPC-157's reputation. Count the humans in the evidence, run four questions, and do the ordinary work first.

What it rests onA solo episode published 30 Jul 2026. She puts the BPC-157 literature at 544 published papers and fewer than 30 human subjects across three uncontrolled pilot trials, a 99.7 percent animal-to-human ratio, and argues that a paper count is the wrong number to be persuaded by. Her four screening questions before any injection are the level of evidence, what the study actually measured, where the vial was sourced, and whether the compound is banned in tested sport. Her safety line: if something is going into your body through a needle, the standard has to be higher than three words on a label saying research use only. She reads the FDA taking a dozen peptides off its safety-concern list in April 2026 as policy pressure rather than new safety data, and closes on the argument that resistance training, protein-anchored nutrition and real recovery beat almost anything in a vial. A storefront under her name sells a BPC plus KPV plus PEA blend at $150, so this is argued against her own commercial interest. She is not against peptides: the episode has a chapter called 'The strongest case for peptides' whose content is in the audio and in no fetchable text.

Timothy CaulfieldProfessor of health law and science policy, University of Alberta; Canada Research Chair 2002 to 2023

No. There is no evidence behind the way this category is being sold, and the market that opened is a policy artefact.

What it rests onHis own words, quoted by himself from a CTV News interview the same day: 'There really is no evidence to support the embrace of peptides in the way that they are being pushed by the wellness and longevity industry.' Across four posts in thirty hours he frames the current market as a wild west opened by policy rather than by data, and points at a compound marketed for cosmetic tanning where the full scope of adverse events is, in the reporting he quotes, still unknown. He is a health law professor rather than a clinician, he sells nothing in this space, and his objection is to the gap between the marketing and the human evidence rather than to research on peptides.